Rheumatoid arthritis (RA) is a chronic inflammatory disease that mainly affects the joints, especially the joints of the hands and feet. The disease is caused by the immune system attacking itself and causing inflammation in the tissues between the joints. RA is more common in women than men and is most common in the 30-60 age group. The disease can cause joint deformity, immobility, and pain. This article provides detailed information about the causes, diagnostic methods, treatment methods, and preventive measures of rheumatoid arthritis. Modern methods such as medications, physiotherapy, and exercise are used to effectively treat rheumatoid arthritis. Early detection and proper treatment of the disease play an important role in improving the patient's overall quality of life.

Rheumatoid arthritis, joints, immune system, inflammation, diagnostics, treatment, biologics, physiotherapy, chronic disease, pain, joint deformity.

Насонов ЕЛ, Каратеев ДЕ, Балабанова РМ. Ревматоидный артрит. В кн.: Насонов ЕЛ, Насонова ВА, редакторы. Ревматология. Национальное руководство. Москва: ГЭОТАР-Медиа; 2008. С. 290-331.

Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. Lancet. 2017;389(10086):2338-48. doi: 10.1016/S0140-6736(17)31491-5

McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017;389(10086):2328-37. doi: 10.1016/S0140-6736(17)31472-1

Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75:3-15. doi: 10.1136/annrheumdis-2015-207524

Combe B, Landewe R, Daien CI, et al. 2016 update of the EULAR recommendations for the management of early arthritis. Ann Rheum Dis. 2016;76:948-59. doi: 10.1136/annrheumdis2016-210602

Stoffer MA, Schoels MM, Smolen JS, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. Ann Rheum Dis. 2016;75:16-22. doi: 10.1136/annrheumdis-2015-207526

Насонов ЕЛ, Каратеев ДЕ, Чичасова НВ. Рекомендации EULAR по лечению ревматоидного артрита – 2013: общая характеристика и дискуссионные проблемы. Научно-практическая ревматология. 2013;51(6):609-22.

Ajeganova S, van Steenbergen HW, van Nies JA, et al. Diseasemodifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms. Ann Rheum Dis. 2016;75(5):867- 73. doi: 10.1136/annrheumdis-2014-207080

Бабамурадова З. Б., Насирова А. А., Искандарова Ф. И. ЭНДОТЕЛИАЛЬНАЯ ДИСФУНКЦИЯ ПРИ ХРОНИЧЕСКОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ В СОЧЕТАНИИ С САХАРНЫМ ДИАБЕТОМ //Journal of cardiorespiratory research. – 2021. – Т. 2. – №. 3. – С. 49-52.

Таджиев Ф. С., Искандарова Ф. И., Кобилова Н. А. Распространенность и факторы риска артериальной гипертонии среди населения Самаркандской области //Тюменский медицинский журнал. – 2017. – Т. 19. – №. 1. – С. 54-58.

Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011;63:573-86. doi: 10.1002/art.30129

Prevoo ML, van Gestel AM, van Thof MA, et al. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol. 1996;35:1101-5. doi: 10.1093/rheumatology/35.11.1101

Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol. 2005;23:S100-8.

Олюнин ЮА. Оценка активности заболевания при ревматоидном артрите: рекомендации и практика. Современная ревматология. 2014;8(2):15-20.

Gaujoux-Viala C, Mouterde G, Baillet A, et al. Evaluating disease activity in rheumatoid arthritis: which composite index is best? A systematic literature analysis of studies comparing the psychometric properties of the DAS, DAS28, SDAI and CDAI. Joint Bone Spain. 2012;79(2):149-55. doi: 10.1016/j.jbspin.2011.04.008

Smolen JS, Collaud Basset S, Boers M, et al. Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease. Ann Rheum Dis. 2016;75(7):1268-71. doi: 10.1136/annrheumdis-2016-209429

Schoels M, Alasti F, Smolen JS, Aletaha D. Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition. Arthritis Res Ther. 2017;19(1):155. doi: 10.1186/s13075-017-1346-5

Cheung PP, Gossec L, Mak A, March L. Reliability of joint count assessment in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum. 2014;43:721-9. doi: 10.1016/j.semarthrit.2013.11.003

Saleem B, Brown AK, Keen H, et al. Should imaging be a component of rheumatoid arthritis remission criteria? A comparison between traditional and modified composite remission scores and imaging assessments. Ann Rheum Dis. 2011;70:792-8. doi: 10.1136/ard.2010.134445

Ferreira RJO, Dougados M, Kirwan JR, et al. Drivers of patient global assessment in patients with rheumatoid arthritis who are close to remission: an analysis of 1588 patients. Rheumatology (Oxford). 2017;56(9):1573-8. doi: 10.1093/rheumatology/kex211